Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JADE101 · 3 trials · 3 indications
The proportion of participants who experience one or more adverse events that begin or worsen after the first dose of study drug
Incidence of treatment-emergent adverse events
Maximum observed serum concentration
Time to reach Cmax
The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration
Apparent first-order terminal elimination half-life
Incidence of treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| JADE101 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| JADE101 Groups 1 and 2 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| JADE101 Groups 3 and 4 | EXPERIMENTAL | Subcutaneous (SC) injection of JADE101 |
| Placebo | PLACEBO_COMPARATOR | Subcutaneous (SC) injection of placebo |
| Name | Type | Description |
|---|---|---|
| JADE101 | DRUG | JADE101 is supplied as sterile solution to be administered by SC injection |
| Placebo | DRUG | Placebo solution to be administered at a matching volume by SC injection. |
Inclusion Criteria: 1. Male or female participants 18-60 years of age, inclusive, and of local legal consenting age at the time of signing the informed consent 2. eGFR ≥ 30 mL/min/1.73 m2 3. Biopsy-confirmed primary IgAN 4. Receiving stable and maximally tolerated doses of either ACEi or ARB as per...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 10 | PHASE3 | BION-1301 |
| Vera Therapeutics, Inc. Class A | VERA | 4 | PHASE3 | Atacicept |
| Travere Therapeutics, Inc. | TVTX | 2 | PHASE3 | sparsentan, irbesartan, Dapagliflozin |
| Biogen Inc. | BIIB | 1 | PHASE3 | Felzartamab |
| AstraZeneca PLC | AZN | 2 | PHASE3 | Ravulizumab |
| Vertex Pharmaceuticals Incorporated | VRTX | 2 | PHASE3 | Povetacicept |
| Biohaven Ltd. | BHVN | 1 | PHASE1 | BHV-1400 |
| Jade Biosciences, Inc. | JBIO | 1 | PHASE2 | JADE101 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-097 |
JADE101 is an investigational small molecule being developed for IgA nephropathy, a kidney disease. It is currently being studied in healthy volunteers to assess safety and tolerability, and in patients with IgA nephropathy to evaluate its potential therapeutic effect. The drug is in Phase 1 and Phase 2 clinical trials.
JADE101 targets APRIL, a cytokine involved in the immune system. By targeting APRIL, JADE101 may modulate the immune response that contributes to IgA nephropathy. This mechanism is being investigated in clinical trials for the treatment of IgA nephropathy.
JADE101 is being developed by Jade Biosciences, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of JADE101 in healthy volunteers and in patients with IgA nephropathy.
JADE101 is in Phase 1 clinical trials for healthy volunteers and Phase 2 clinical trials for IgA nephropathy. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical development to assess its safety and effectiveness.
JADE101 is being studied in three clinical trials. NCT07059312 is a Phase 1 study in healthy participants in New Zealand. NCT07525947 is a Phase 1 single-dose study in healthy Japanese and Chinese participants in the United States. NCT07541287 is a Phase 2 study in participants with IgA nephropathy across multiple countries.
No, JADE101 is not the same as APRIL. APRIL is a cytokine that JADE101 targets. JADE101 is a small molecule drug designed to interact with APRIL to potentially treat IgA nephropathy. The drug itself is distinct from its molecular target.